

Linda Sofie Lindström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6091320/publications.pdf>

Version: 2024-02-01

28
papers

619
citations

623734

14
h-index

610901

24
g-index

30
all docs

30
docs citations

30
times ranked

1253
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. <i>JAMA Oncology</i> , 2017, 3, 1503.	7.1	91
2	Long-term outcome in young women with breast cancer: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 131-143.	2.5	82
3	Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 726-733.	6.3	55
4	The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. <i>Breast Cancer Research</i> , 2019, 21, 34.	5.0	48
5	Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 7512-7520.	7.0	43
6	Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1304.	7.1	33
7	Breast cancer in young women and prognosis: How important are proliferation markers?. <i>European Journal of Cancer</i> , 2017, 84, 278-289.	2.8	24
8	Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients. <i>Molecular Oncology</i> , 2014, 8, 741-752.	4.6	23
9	A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. <i>Oncogene</i> , 2020, 39, 5430-5440.	5.9	23
10	Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. <i>Molecular Oncology</i> , 2016, 10, 517-525.	4.6	21
11	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7225-7231.	7.0	17
12	Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 593-601.	2.5	17
13	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014, 5, 4051.	12.8	16
14	Differences in survival for patients with familial and sporadic cancer. <i>International Journal of Cancer</i> , 2017, 140, 581-590.	5.1	16
15	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 2584-2592.	7.0	15
16	Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. <i>JAMA Network Open</i> , 2021, 4, e2114716.	5.9	14
17	Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. <i>Molecular Oncology</i> , 2015, 9, 1384-1391.	4.6	13
18	Cause-specific mortality in women with breast cancer <i>in situ</i> . <i>International Journal of Cancer</i> , 2017, 140, 2414-2421.	5.1	13

#	ARTICLE	IF	CITATIONS
19	Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy. <i>JAMA Network Open</i> , 2021, 4, e2114904.	5.9	12
20	Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa087.	2.9	11
21	Site-specific familial risk and survival of familial and sporadic head and neck cancer. <i>International Journal of Cancer</i> , 2017, 141, 497-502.	5.1	10
22	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2417-2426.	7.0	8
23	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. <i>Npj Breast Cancer</i> , 2021, 7, 2.	5.2	7
24	Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature. <i>International Journal of Cancer</i> , 2022, 150, 2072-2082.	5.1	7
25	Sequential metastatic biopsies and functional imaging in breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22120-e22120.	1.6	0
26	There is more to the picture than meets the eye: Population-based study on biopsy verification of suspected breast cancer recurrences.. <i>Journal of Clinical Oncology</i> , 2015, 33, 542-542.	1.6	0
27	Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22090-e22090.	1.6	0
28	Gene expression of metastatic biopsies for prediction of response to palliative chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1044-1044.	1.6	0